Login / Signup

Chronic Active T-Cell Mediated Kidney Rejection as a Clinically Significant Type of Allograft Loss?

Jakub MizeraJustyna PilchDorota KamińskaMagdalena KrajewskaPiotr DonizyMirosław Banasik
Published in: Diagnostics (Basel, Switzerland) (2022)
The purpose of this article is to assess the present knowledge about chronic active (CA) T-cell mediated rejection (TCMR) of a kidney. In the research authors review current Banff diagnostic criteria used in kidney rejection, focus on their possible future evolution, and investigate the role of currently available molecular methods that could be implemented into the diagnostic scheme. Research also points out previously and currently available treatment methods applied to CA TCMR and takes into account possible side effects consequent upon the therapy. Moreover, attention is being paid to the CA TCMR coincidence with other kidney rejection types such as antibody-mediated rejection (ABMR) and its influence on the treatment approach. Authors also mark the possibility of non-HLA antibodies coexistence in patients with CA TCMR and describe its possible resonance on kidney allograft function. Nonetheless, it seems that current knowledge about CA TCMR is not sufficient and requires further investigation.
Keyphrases
  • healthcare
  • protein kinase
  • mesenchymal stem cells
  • combination therapy
  • bone marrow
  • current status
  • single molecule
  • energy transfer
  • chemotherapy induced